Condition category
Mental and Behavioural Disorders
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Background and study aims
Attention deficit hyperactivity disorder (ADHD) is a common disorder that affects behaviour. ADHD can present in a number of ways, but common symptoms include a short attention span, restlessness, hyperactivity and impulsiveness. It is a common disorder in children, with around 5-10% of European children being affected, and around a third of these cases are expected to continue into adulthood. Initial treatment for ADHD usually involves medication however this can lead to severe side effects and is not always effective. One proposed alternative treatment which doesn’t cause these side effects is neurofeedback. Neurofeedback in general is defined as a procedure during which a participant learns self-control over brain functioning through getting feedback on it from MRI brain scanning. This aims to help eliminate patterns in the way the brain signals within itself leading to abnormal behavior. The goal in ADHD patients is to teach participants how to control certain brain signals that are an indicator of alertness. Recent reviews on EEG-neurofeedback have concluded that preliminary results are promising regarding the reduction of ADHD symptoms and improvement of genitive functioning (thought, memory and learning). The aim of this study is to investigate the effectiveness of neurofeedback treatment in patients with ADHD.

Who can participate?
Adults with ADHD who are not currently receiving drug treatment.

What does the study involve?
Before the training, participants are given a set of cognitive (thinking) strategies that they may use during the neurofeedback training (e for all participants). These cognitive strategies are taken from research looking into which mental tasks activate the get areas of the brain. During the neurofeeback, participants are in an MRI scanner and are able to see their brain activation on a screen. Participants are randomly allocated to two groups. Those in the first group are able to see the area of the brain responsible for their ADHD symptoms, and those in the second group see a “control area” (i.e. an area not responsible for the symptoms that is still activated). Participants in both groups are then instructed to increase and maintain activation levels to a set target level, in order to learn how to control their brain signalling. Before and after the training, participants in both groups complete a number of tasks to measure their cognitive function and a questionnaire to measure their ADHD symptoms.

What are the possible benefits and risks of participating?
Participants may benefit from an improvement to their ADHD symptoms as a result of the treatment. There are no notable risks involved with participating

Where is the study run from?
Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre (Netherlands)

When is the study starting and how long is it expected to run for?
March 2012 to September 2014

Who is funding the study?
BrainGain Consortium (Netherlands)

Who is the main contact?
1. Dr Anna Zilverstand
2. Professor Jan K Buitelaar

Trial website

Contact information



Primary contact

Dr Anna Zilverstand


Contact details

Department of Psychiatry
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place
Box 1230
New York
NY 10029
United States of America



Additional contact

Prof Jan K Buitelaar


Contact details

Donders Institute for Brain
Cognition and Behaviour
Kapittelweg 29
6525 EN
+31 24 36 53276

Additional identifiers

EudraCT number number

Protocol/serial number

Registratienummer: 2012/292 NL nr.: 40273.091.12

Study information

Scientific title

Increasing anterior cingulate cortex activation in adult attention deficit hyperactivity disorder: a real-time fMRI neurofeedback feasibility study


Study hypothesis

Primary objective:
To investigate whether the modulation of the ACC activation level through fMRI-neurofeedback training reduces ADHD symptoms and improves cognitive functioning.

Secondary objective:
To investigate if abnormal activation levels of the ACC in ADHD patients play a causal role in ADHD pathophysiology.

Ethics approval

The Commissie Mensgebonden Onderzoek (Central Comittee on Research Involving Human Subjects) Regio Arnhem-Nijmegen, 27/09/2012, ref: 2012/292 and 40273.091.12

Study design

Single-center single-blind randomized controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet


Attention Deficit Hyperactivity Disorder


Before the training the subjects will be suggested a set of cognitive strategies that they may use during the neurofeedback training (the same set of strategies in both groups). These cognitive strategies will be derived from research on which mental tasks activate the neurofeedback and the control region. Towards the patients it will be stressed that they are also always free to choose any other strategy that seems to work, and that they should be guided by the feedback in the selection of their strategy.

During the neurofeeback training the patients randomly allocated to either see their own current brain activation level (BOLD % signal change) from the individually defined feedback target region in the dorsal anterior cingulate cortex (experimental group), or the control region (control group). They will see the current activation level presented with a simple a visual thermometer display, which will be continuously updated (every 1.5 second). The thermometer will be individually scaled according to the activation level measured during the previous localizer task. Participants will be instructed to increase and maintain activation levels to a 50% or to a 100% level, depending on the target level indicated by the red box. The subjects will have no other task than to using mental strategies to manipulate their brain activation level and observe and reflect on the changes in the displayed activation level while they are doing this.

The training will last approximately 30 minutes and consist of 3x 8 “neurofeedback” blocks of 30 seconds during which they will manipulate their brain activation, each neurofeedback block being followed by a resting period of 20 seconds. After a series of 8 blocks there will be a self-paced break. Finally, 8 “transfer” blocks will follow, during which subjects will be asked to apply whatever strategy they have learned previously, but now without receiving neurofeedback. They will thus be asked to transfer what they have learned during the training to a situation without neurofeedback.

Intervention type



Drug names

Primary outcome measure

The severity of ADHD symptoms are measured using the ADHD-DSM-IV rating scale fully based on the DSM-IV before and after training.

Secondary outcome measures

1. Sustained attention is measured using both the Sustained Attention dots task (SA-DOTS) as well as the Sustained Attention to Response Task (SART) before and after training
2. Working memory is measured using the Digit Span subtest of the WAIS-III-NL to assess verbal working memory and the visuo-spatial Nback task to assess visuo-spatial working memory before and after training
3. Cognitive control during interference is measured using the Multi-Source Interference Task before and after training

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Diagnosis of ADHD according to the DSM-IV TR criteria (American Psychiatric Association, 2000)
2. Aged 18 years and over
3. Psychopharmaca-naïve or –free, or being on a fixed dose of medication for the study period (patients may pro-actively opt for non-medical treatment)
4. Passing fMRI screening criteria, which consist of the following:
4.1. No previous brain operation
4.2. No epilepsy
4.3. No implants as for example pacemakers or an implanted insulin pump
4.4. No metal parts in the body (protheses, implants, clips on blood vessels, spiral, or other metal objects except teeth fillings and connectors)
4.5. No claustrophobia
4.6. No pregnancy
4.7. IQ > 100 according to block design and vocabulary test WAIS-III-NL (Uterwijk, 2005)

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Participation in another clinical trial simultaneously
2. Previous participation in neurofeedback training
3. Other significant medical condition (e.g. neurological, heart or vascular diseases) or regular use of medication other than psychostimulants if the dosis of medication is not fixed for the study period
4. Current diagnosis of one or more Axis I diagnosis other than ADHD according to the DSM-IV TR criteria (American Psychiatric Association, 2000) (e.g. depression, psychosis, tics, autism, eating disorders or behavioural disorders)
5. Current alcohol or drug abuse according to the DSM-IV TR criteria (American Psychiatric Association, 2000)

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Donders Institute for Brain, Cognition and Behaviour
Radboud University Nijmegen Medical Centre Kapittelweg 29
6525 EN

Sponsor information


BrainGain Consortium

Sponsor details

Heyendaalseweg 135
6525 AJ

Sponsor type

Research council



Funder type

Research organisation

Funder name

BrainGain Consortium

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

The results of this study will be submitted to peer-reviewed journals for publication.

Intention to publish date


Participant level data

Available on request

Basic results (scientific)

Publication list

2017 results in:

Publication citations

Additional files

Editorial Notes

20/10/2017: Publication reference added.